Drug repurposing for rare disease treatment leads to reduced risk Director of the Drug Discovery Platform of Parc Científic Barcelona (PCB), Jordi Quintana and his team secured funding to investigate a rare disease, amyloidosis. They set out to study a subset of the disease called familial amyloid polyneuropathy (FAP). Because of the rare nature of the disease and the limited patient base, traditional drug discovery and development techniques were not an option. As a result, Quintana turned his attention to repurposing as a viable strategy for drug discovery. “This approach involves the investigation of pharmaceutical compounds already on the market, or in advanced clinical phases, which were initially developed for different therapeutic applications that might also

Join for free to read